Amneal Q3 revenue beats estimates on affordable medicines growth; outlook raised
Overview
US generics and specialty drugmaker's Q3 revenue rose 10%, beating analyst expectations
Adjusted EPS for Q3 beat analyst expectations, up 53% year-over-year
Company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS
Outlook
Amneal raises 2026 net revenue guidance to $3.15 bln-$3.25 bln from $3.10 bln-$3.20 bln
Company now expects 2026 adjusted EBITDA of $800 mln-$815 mln, up from $750 mln-$780 mln
Amneal sees 2026 adjusted diluted EPS at $1.04-$1.08, up from $0.96-$1.06
Result Drivers
AFFORDABLE MEDICINES GROWTH - Revenue from Affordable Medicines rose 19%, driven by biosimilars, women’s health patches, and new launches
SPECIALTY SEGMENT GROWTH - Specialty net revenue increased 20%, led by branded products including CREXONT, BREKIYA autoinjector, and UNITHROID
AVKARE DECLINE - AvKARE net revenue fell 17% due to a non-recurring cardiovascular product launch in the prior year
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $863 mln | $815.86 mln (6 Analysts) |
Q3 Adjusted EPS | Beat | $0.26 | $0.23 (7 Analysts) |
Q3 Net Loss | $22 mln | ||
Q3 Adjusted EBITDA | $207 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Amneal Pharmaceuticals, Inc is $24.00, about 17.4% above its November 2 closing price of $20.44
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 17 three months ago
Reuters Recommended Reads
Nov 2 - Dr Reddy's gets tentative US FDA nod for generic HIV prevention
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 2 - Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)